{"id":2916,"date":"2022-09-04T17:58:18","date_gmt":"2022-09-04T17:58:18","guid":{"rendered":"https:\/\/palynziqhcp-dev-001.azurewebsites.net\/en-us\/palynziq\/?page_id=2916"},"modified":"2024-06-12T13:37:20","modified_gmt":"2024-06-12T13:37:20","slug":"dosing-administration","status":"publish","type":"page","link":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/dosing-administration\/","title":{"rendered":"Dosing & Administration"},"content":{"rendered":"
\n
\n
<\/div>\n
<\/div>\n
<\/div>\n
\n
\n
\n

Dosing & Administration\n<\/h1>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n
\n
\n
\n \n
\n

PALYNZIQ is a daily at-home subcutaneous injection available in 3 different dosage strengths to help patients achieve their blood Phe goals1,2<\/sup><\/h2>\n <\/div>\n\n
\n
\n
\n\t\t\t \"Syringes\"\t\t\t<\/div>\n\t\t\t
\n\t\t\t \"Syringes\"\t\t\t<\/div>\n <\/div>\n <\/figure>\n\n
\n
    \n
  • PALYNZIQ\u00ae<\/sup> (pegvaliase-pqpz) Injection is supplied in a prefilled syringe1<\/sup>\n
      \n
    • Not auto-injectable<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n
        \n
      • PALYNZIQ should be refrigerated at 36\u00b0F (2\u00b0C) to 46\u00b0F (8\u00b0C)<\/strong> in the original carton to protect from light1<\/sup><\/li>\n
      • PALYNZIQ can be safely stored in the original carton at room temperature between 68\u00b0F (20\u00b0C) to 77\u00b0F (25\u00b0C)<\/strong> for up to 30 days1<\/sup>\n
          \n
        • On the carton, patients should record the date that they remove PALYNZIQ from the refrigerator<\/li>\n
        • Do not re-refrigerate once stored at room temperature<\/li>\n<\/ul>\n<\/li>\n
        • PALYNZIQ maintenance doses can be individualized based on patient tolerability, blood Phe, and dietary needs1<\/sup><\/li>\n<\/ul>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n
          \n
          \n
          \n \n
          \n

          PALYNZIQ dosage is gradually increased to help reach an optimal dose based on patient tolerability, blood Phe levels, and protein intake1<\/sup><\/h2>\n

          The first injection must be performed under the supervision of a healthcare provider.1<\/sup><\/strong><\/p>\n <\/div>\n\n

          \n
          \n \"Recommended <\/div>\n

          *Additional time may be required prior to each dosage escalation based on patient tolerability.
          \n\u2020Individualize treatment to the lowest effective and tolerated dosage. Consider increasing to 40 mg once daily in patients who have not achieved a response with 20 mg once daily continuous treatment for at least 24 weeks. Consider increasing to a maximum of 60 mg once daily in patients who have not achieved a response with 40 mg once daily continuous treatment for at least 16 weeks. The first injection must be performed under the supervision of a healthcare provider.1<\/sup>
          \n\u2021Discontinue PALYNZIQ in patients who have not achieved an adequate response after 16 weeks of continuous treatment at the maximum dosage of 60 mg once daily. The interpretation of ‘adequate response’ is left up to the discretion of the healthcare provider.<\/small><\/p>\n<\/figcaption>\n <\/figure>\n <\/div>\n <\/div>\n<\/div>\n\n

          \n
          \n
          \n <\/div>\n <\/div>\n<\/div>\n\n
          \n
          \n\t\t
          \n\t\t\t
          \n\t\t\t\t
          <\/div>\n\t\t\t\t
          \n\t\t\t\t \t\t\t\t\t
          \n
          \n\t\t\t\t\t \t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t

          In clinical trials, the majority of patients (89\/118) achieved blood Phe levels \u2264360 \u00b5mol\/L. Of those who achieved \u2264360 \u00b5mol\/L following the titration schedule (58\/118)2<\/sup>:<\/h4>\n
            \n

            \n
          • 50% (29\/58) achieved \u2264360 \u00b5mol\/L on a 20 mg dose<\/li>\n
          • 38% (22\/58) achieved \u2264360 \u00b5mol\/L on a 40 mg dose<\/li>\n
          • 12% (7\/58) achieved \u2264360 \u00b5mol\/L on a 60 mg dose<\/li>\n<\/ul>\n<\/h4>\n\t\t\t\t\t\t \t\t\t\t\t <\/div>\n\t\t\t\t\t <\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n
            \n
            \n\t\t
            \n\t\t \t\t\t

            References:\n<\/h4>\n\t\t\t\t\t\t
              \n
            1. PALYNZIQ [package insert]. Novato, CA: BioMarin Pharmaceutical Inc; 2020.\n<\/span><\/li>\n
            2. PALYNZIQ [instructions for use]. Novato, CA: BioMarin Pharmaceutical Inc; 2020.\n<\/span><\/li>\n <\/ol>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"acf":[],"yoast_head":"\nDosing and Administration | Palynziq HCP<\/title>\n<meta name=\"description\" content=\"PALYNZIQ is a daily at-home subcutaneous injection available in 3 different dosage strengths to help patients achieve their blood Phe goals.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/dosing-administration\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dosing and Administration | Palynziq HCP\" \/>\n<meta property=\"og:description\" content=\"PALYNZIQ is a daily at-home subcutaneous injection available in 3 different dosage strengths to help patients achieve their blood Phe goals.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/dosing-administration\/\" \/>\n<meta property=\"og:site_name\" content=\"BioMarin Palynziq HCP EN-US\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-12T13:37:20+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/dosing-administration\/\",\"url\":\"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/dosing-administration\/\",\"name\":\"Dosing and Administration | Palynziq HCP\",\"isPartOf\":{\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/#website\"},\"datePublished\":\"2022-09-04T17:58:18+00:00\",\"dateModified\":\"2024-06-12T13:37:20+00:00\",\"description\":\"PALYNZIQ is a daily at-home subcutaneous injection available in 3 different dosage strengths to help patients achieve their blood Phe goals.\",\"breadcrumb\":{\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/dosing-administration\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/dosing-administration\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/dosing-administration\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dosing & Administration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/#website\",\"url\":\"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/\",\"name\":\"BioMarin Palynziq HCP EN-US\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dosing and Administration | Palynziq HCP","description":"PALYNZIQ is a daily at-home subcutaneous injection available in 3 different dosage strengths to help patients achieve their blood Phe goals.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/dosing-administration\/","og_locale":"en_US","og_type":"article","og_title":"Dosing and Administration | Palynziq HCP","og_description":"PALYNZIQ is a daily at-home subcutaneous injection available in 3 different dosage strengths to help patients achieve their blood Phe goals.","og_url":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/dosing-administration\/","og_site_name":"BioMarin Palynziq HCP EN-US","article_modified_time":"2024-06-12T13:37:20+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/dosing-administration\/","url":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/dosing-administration\/","name":"Dosing and Administration | Palynziq HCP","isPartOf":{"@id":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/#website"},"datePublished":"2022-09-04T17:58:18+00:00","dateModified":"2024-06-12T13:37:20+00:00","description":"PALYNZIQ is a daily at-home subcutaneous injection available in 3 different dosage strengths to help patients achieve their blood Phe goals.","breadcrumb":{"@id":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/dosing-administration\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hcp.biomarin.com\/en-us\/palynziq\/dosing-administration\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/dosing-administration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/"},{"@type":"ListItem","position":2,"name":"Dosing & Administration"}]},{"@type":"WebSite","@id":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/#website","url":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/","name":"BioMarin Palynziq HCP EN-US","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/wp-json\/wp\/v2\/pages\/2916"}],"collection":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/wp-json\/wp\/v2\/comments?post=2916"}],"version-history":[{"count":80,"href":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/wp-json\/wp\/v2\/pages\/2916\/revisions"}],"predecessor-version":[{"id":6688,"href":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/wp-json\/wp\/v2\/pages\/2916\/revisions\/6688"}],"wp:attachment":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/wp-json\/wp\/v2\/media?parent=2916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}